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above. There is uncertainty, however, regarding the effectiveness of oxaliplatin 
in combination adjuvant chemotherapy for prevention of mortality in this 
population. Oxaliplatin’s rapid adoption for treatment of stage III colon cancer 
patients in 2004 provides an opportunity to use calendar time as an instrumental 
variable (IV) in nonexperimental comparative effectiveness research. This 
method makes assumptions different from covariate adjustment and may thus 
enhance our understanding of treatment effects. METHODS: We examined 
patients aged 65+ initiating chemotherapy between 2003-08 using population-
based cancer registry data linked with Medicare claims (N=3660). We derived risk 
of all-cause mortality from Kaplan-Meier survival curves and estimated risk 
differences (RD). We examined IV strength and compared RDs with propensity 
score (PS)-matched estimates. RESULTS: Calendar time greatly affected 
treatment receipt. The optimal 2-level calendar time instrument achieved a 
strength of 53.97% compliance by grouping patients treated from January 2003 
through September 2004 (n=1449) and those treated from March 2005 through 
May 2007 (n=1432). The 1-,2-,3-year Wald IV RDs (95% confidence interval) were  
-0.05 (-0.09, -0.01), -0.07 (-0.12, -0.01), -0.09 (-0.15, -0.03), respectively. PS-adjusted 
1-,2-,3-year RDs were -0.02(-0.04,0), -0.03(-0.06,-0.01), -0.04(-0.08,-0.01). 
CONCLUSIONS: IV and PS-adjusted models both indicate a survival advantage in 
this population of older patients treated with oxaliplatin, albeit with different 
point estimates. As these RDs are based on different assumptions and apply to 
different populations, the IV analysis strengthens evidence of oxaliplatin’s 
effectiveness in older adults, who bear the greatest burden of colon cancer yet 
were underrepresented in oxaliplatin clinical trials. In nonexperimental CER of 
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OBJECTIVES: Since the 1970s, cancer incidence and mortality have been 
increasing rapidly in China. The purpose of this study was to project cancer 
incidence of the fourteen major cancers in China from 2010 to 2030 by evaluating 
the potential effects of the population growth, change in age structure, and 
urbanization. METHODS: A demographic approach was taken for projection. 
Cancer incidence rates, projected populations, and urbanization rates were 
obtained or derived based on the database from the Chinese cancer registry 
office, the U.S. census bureau, and the Department of Economic and Social 
Affairs of the United Nations, respectively. Incidence rates and population data 
were categorized by area (rural vs urban), gender (male vs female), and age  
(5-year age groups). Cancer incidence was projected by applying the area-, 
gender-, and age-specific incidence rates of each cancer to the corresponding 
subpopulations in 2010, and 2030 respectively. The fourteen tumor types 
included cancers of the bladder, breast, cervix, colorectum, esophagus, head and 
neck, kidney, liver, lung, melanoma, ovary, pancreas, prostate, and stomach. 
RESULTS: Compared with 2010, the incidence of the fourteen major cancers in 
China will increase by 64.3% in 2030 from 2.6 million to 4.3 million. The urban 
incidence population and the senior incidence population (>=65 years old) will be 
more than doubled (from 1.1 to 2.5 million, and 1.2 to 2.5 million respectively). 
The top five cancers (lung, stomach, liver, esophagus, and colorectum) accounted 
for more than 77.5% of the fourteen major cancers in 2010, and they will increase 
by 55.8% from 2.2 million to 3.5 million in 2030. Cancers of the prostate, bladder, 
colorectum, pancreas, and lung are among the fastest growing cancers. 
CONCLUSIONS: The aging population and the accelerated urbanization trend in 
China will drastically increase cancer incidence in the near future, and this will 
impose a significant economic burden on the health care system.  
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OBJECTIVES: Surgical outcomes are associated with patient and surgeon 
characteristics. If outcomes are also independently impacted by the specific 
hospital where the surgery occurs, there is a hospital center effect (HCE). This 
study is to examine HCE among elderly stage l-lll colon cancer patients with 
laparoscopic colectomies. METHODS: The Surveillance, Epidemiology and End 
Results (SEER)-Medicare dataset was used to identify stage I-III colon cancer 
patients in 2003 to 2007 with laparoscopic colectomies. Multilevel model 
regressions were utilized to study potential HCE for length of stay (LOS), 30-day 
re-hospitalization, and in-hospital mortality, adjusting for patient, surgeon and 
hospital level characteristics. To quantify the impact of HCE, we calculated 
median instantaneous rate ratio (MIRR) for LOS and median odds ratio (MOR) for 
in-hospital mortality and 30-day re-hospitalization. Sensitivity analyses were 
also conducted for high volume/medical school affiliated hospitals and colorectal 
surgeons. RESULTS: The multilevel analyses based on 4,617 patients from 465 
hospitals documented significant HCEs for LOS (MIRR = 1.36; p < 0.001) and in-
hospital mortality (MOR=1.72; p=0.037), but no HCE for 30-day re-hospitalization. 
For patients with Charlson comorbidity index (CCI) greater than or equal to 3, 
MIRR rose to 2.27 for LOS and MOR rose to 6.87 for in-hospital mortality, as 
compared to patients with CCI = 1. The sensitivity analyses confirmed our 
findings. HCE was significant for LOS in all subgroup analyses, and was 
significant for in-hospital mortality for high volume/medical school affiliated 
hospitals. CONCLUSIONS: HCE is an important source of variation for 
laparoscopy outcomes, and it is still significant when patient, provider and 
hospital level characteristics are adjusted. HEC exists for both LOS and in-
hospital mortality. The findings are robust to high volume/medical school 
affiliated hospitals and colorectal surgeons. HCE is a potential area to improve 
the quality of care for stage I-III laparoscopic colon cancer patients.  
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OBJECTIVES: To determine the impact of body mass index (BMI) on prognosis for 
patients with breast cancer. METHODS: Electronic medical records from a 
network of 9 hospitals were linked to female breast cancer patients who were 
diagnosed between 2007 and 2010 in Florida. Cox proportional hazards model 
was used to assess cause-specific survival. RESULTS: A total of 1368 patients 
with the diagnosis of breast cancer were identified. African American patients 
comprised 9.02%. Median follow-up time for those who died due to breast cancer 
was 709 days. Two-year survival was 94.7%. Overweight or obese patients were 
not significantly different from patients of normal weight in breast cancer 
survival. Breast cancer death rate for underweight patients was 2.1 times that of 
normal weight patients (p = 0.038). The proportion of underweight patients 
among those who died due to breast cancer was 13.21%, the highest compared to 
those in other groups. Multivariable analysis revealed an increased hazard 
associated with low BMI, triple negative biomarker status, distant stage, larger 
tumors, more positive nodes identified, and Medicare users. Lower hazard of 
breast cancer death was associated with more nodes examined. CONCLUSIONS: 
Underweight is associated with poorer prognosis in breast cancer patients. 
Neither overweight nor obese groups was associated with a significantly altered 
risk of breast cancer death following diagnosis. Mechanisms to understand the 
poorer prognosis for underweight patients need to be defined. Findings of this 
study suggest that weight management for underweight breast cancer patients 
and increase body weight to normal weight may deserve examination.  
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OBJECTIVES: Optimal therapy and associated survival benefit for patients with 
stages IIIB/C and IV colorectal cancer (CRC) have not been well established. The 
aim of this study was to examine treatment patterns and survival among CRC 
patients who received 2nd and 3rd line regimens. METHODS: A retrospective 
analysis was performed using the Georgia Cancer Specialist Database. Patients 
18 years and older diagnosed with stage IIIB/C or IV CRC between January, 2006 
and November, 2012 were followed from initial CRC diagnosis until death, study 
end or loss to follow-up. Regimen concordance with National Comprehensive 
Cancer Network (NCCN) treatment guidelines was assessed. Survival was 
compared between patients who initiate second- versus third-line regimens 
using Cox proportional hazards models. RESULTS: 1081 patients were identified, 
542 with stage IIIB/C and 539 with stage IV CRC. The most common first line 
regimens were FOLFOX (32% of patients) and FOLFOX with bevacizumab (18% of 
patients). In discordance with the NCCN guidelines, 16% of patients received 
monotherapy as first line. 544 patients (50%) received second line therapy; the 
most common regimen was bevacizumab plus IFL (14% of patients who received 
second line therapy). Approximately 25% of patients (n=269) received third line 
therapy. The most common therapies were irinotecan/cetuximab, bevacizumab 
monotherapy, and capecitabine monotherapy (10% of 3rd line patients, 
respectively). 73% of 3rd line patients had ECOG performance scores of zero or 
one. Survival was significantly worse in stage IV patients who received 3rd line 
therapy versus those who stopped at 2nd line (p=0.004). CONCLUSIONS: Most 
patients received treatment in accordance with NCCN guidelines; however, a 
substantial proportion received monotherapy as first line. There was no survival 
benefit observed in stage IV patients who began a third line therapy. The 
subpopulation of patients who may benefit from 3rd line therapy should be 
explored in future studies.  
 
PCN19  
PATIENT SURVIVAL FOLLOWING MALIGNANT BRAIN TUMOR RESECTION 
USING A LINKED CLAIMS DATABASE  
Bonafede MM1, Lenhart GM1, Chang S2 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Washington, DC, 
USA  
OBJECTIVES: To describe patient characteristics and survival in a cohort of 
commercially insured individuals with incident malignant brain tumors. 
METHODS: The Truven Health Analytics MarketScan Research Databases were 
used to identify adults with incident malignant neoplasm of the brain (191.xx) 
who underwent brain surgery (index event) during 2006-2010. Patients were 
required to have 6 months of continuous enrollment prior to the index surgery 
and were excluded if they received chemotherapy, temozolomide, or brain 
surgery or had another primary or secondary cancer during the pre-index period. 
Eligible patients were then linked to the Social Security Administration (SSA) 
master death files. The SSA death files indicate the presence and date of death. 
The combined dataset was used to describe patient characteristics, post-surgery 
